Breakthrough in Cancer Gene Therapy: Immunotherapy Showing Promise

Strategic Insights -

Researchers at AHEPA University Hospital in Greece have reported promising results in using immunotherapy as a treatment for non-small cell lung cancer in inoperable patients. According to the study, programmed death-ligand 1 (PD-L1) is a valuable marker for the success of immunotherapy, and patients with a higher PD-L1 score are more likely to experience successful treatment outcomes. However, the study also highlights that immunotherapy can be effective even in patients with a lower PD-L1 score, and it can be administered as a first-line treatment with the addition of chemotherapy or radiotherapy.

Key Takeaways:

  • Immunotherapy is considered a promising treatment for non-small cell lung cancer in inoperable patients, with high potential for success in patients with a higher PD-L1 score.
  • Programmed death-ligand 1 (PD-L1) is a valuable marker for the success of immunotherapy, with patients having a higher PD-L1 score experiencing more successful treatment outcomes.
  • Immunotherapy can be effective even in patients with a lower PD-L1 score, making it a viable option for first-line treatment in these patients.
  • The main issue for patients undergoing immunotherapy is adverse effects, particularly pneumonitis, which can be diagnosed early through lung parenchyma sampling with cryobiopsy.
  • Researchers are exploring alternative treatment modalities, such as gene therapy with immunotherapy, to improve treatment outcomes for patients with low PD-L1 scores.

Statistics:

  • 50% PD-L1 score: patients with this score experience more successful treatment outcomes with immunotherapy.
  • 0% PD-L1 score: patients with this score can still benefit from immunotherapy as a first-line treatment with the addition of chemotherapy or radiotherapy.
  • 39% of patients in the study had a PD-L1 score of 50% or higher.
  • 61% of patients in the study had a PD-L1 score of 0% or lower.

Sources:

  • Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy. Respiratory Medicine Case Reports, 2022, 39():101741. (Respiratory Medicine Case Reports - http://www.journals.elsevier.com/respiratory-medicine-case-reports/).
  • NewsRx. Researchers at AHEPA University Hospital Zero in on Cancer Gene Therapy (Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy). Immunotherapy Weekly. October 5, 2022; p 29.